A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary

International Journal of Clinical Oncology

Volumn 18, Issue 2, 2013, Pages 226-231

  Carlson, Heather ^a   Lenzi, Renato ^a   Raber, Martin N ^a   Varadhachary, Gauri R ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Carcinoma of unknown primary; Gemcitabine; Oxaliplatin

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 7; GEMCITABINE; OXALIPLATIN;

ADULT; AGED; ANOREXIA; ARTICLE; BACKACHE; BODY TEMPERATURE DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLD INTOLERANCE; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; STOMACH OBSTRUCTION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG TOXICITY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; ORGANOPLATINUM COMPOUNDS;

EID: 84880916267     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0366-4     Document Type: Article

References (25)

1. Abbruzzese JL, Abbruzzese MC, Hess KR et al (1994) Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12(6):1272-1280
2. Glover K, Varadhachary GR, Lenzi R et al (2008) Unknown primary cancer. In: Abelhoff M (ed) Clinical oncology, 4th edn. Elsevier, Philadelphia, pp 2057-2074
3. Bugat R, Bataillard A, Lesimple T et al (2002) Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site. Br J Cancer 89(Suppl 1):S59-S66
4. Hainsworth JD, Erland JB, Kalman LA et al (1997) Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 15(6):2385-2393
5. Briasoulis E, Kalofonos H, Bafaloukos D et al (2000) Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 18(17):3101-3107
6. Briasoulis E, Fountzilas G, Bamias A et al (2008) Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a Hellenic Cooperative Oncology Group study. Cancer Chemother Pharmacol 62(2):277-284
7. Schneider BJ, El-Rayes B, Muler JH et al (2007) Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer 110(4):770-775
8. Palmeri S, Lorusso V, Palmeri L et al (2006) Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II study. Cancer 107(12):2898-2905
9. Hainsworth JD (2006) Bevacizumab plus erlotinib in patients (pts) with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 24(18S):3033
10. Hainsworth JD, Spigel DR, Raefsky EL et al (2005) Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial. Cancer 104(9):1992-1997
11. Faivre S, Raymond E, Woynarowski JM et al (1999) Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44(2):117-123
12. Faivre S, Chan D, Salinas R et al (2003) DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66(2):225-237
13. Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23(15):3509-3516
14. Weissman C, Reynold C, Neubauer M et al (2011) A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 6(2):358-364
15. Franciosi V, Barbieri R, Aitini E et al (2003) Gemcitabine and oxaliplatin: a safe and active regimen in poor-prognosis advanced non-small cell lung cancer patients. Lung Cancer 41(1):101-106
16. Halim A, Ebrahim M, Saleh Y (2011) A phase II study of outpatient biweekly gemcitabine-oxaliplatin in advanced biliary tract carcinomas. Jpn J Clin Oncol 41(2):217-224
17. Andre T, Reyes-Vidal JM, Fartoux L et al (2008) Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 99(6):862-867
18. Varadhachary G, Talantov D, Raber M et al (2008) Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26(7):4442-4448
19. Louvet C, André T, Lledo G et al (2002) Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20(6):1512-1518
20. Alberts SR, Townley PM, Goldberg RM et al (2003) Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol 14(4):580-585
21. Therasse P, Arbuck S, Eisenhauer E et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205-216
22. Varadhachary GR, Raber MN, Matamoros A et al (2008) Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 9(6):596-599
23. Tot T (1999) Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer 85(1):171-177
24. Rubin BP, Skarin AT, Pisick E et al (2001) Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev 10(1):77-82
25. Varadhachary GR, Spector Y, Abbruzzese JL et al (2011) Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 17(12):4063-4070